相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1970
已完成
1
100.0%
暂无批准数据
- King Faisal Specialist Hospital & Research Centre will present its tertiary care AI dataset strategy at HLTH Europe 2026 in Amsterdam from June 15–18. - The hospital's genomic medicine program nearly doubled testing from approximately 22,000 tests in 2022 to more than 44,000 in 2024, with over 5,000 precision oncology analyses completed. - Pharmacogenomic alerts activated during the period altered treatment in 70% of documented cases, demonstrating real-world clinical impact. - KFSH has submitted nearly 8,000 variants to ClinVar, including close to 3,000 Arab population-specific variants, 34% of which are absent from the Genome Aggregation Database.
- King Faisal Specialist Hospital & Research Centre successfully treated the first patient using locally-manufactured CAR-T cells as part of a Phase I clinical trial for relapsed acute lymphoblastic leukemia. - The hospital conducted 48% of all clinical trials registered in Saudi Arabia during the first half of 2025, with 104 active trials and 80 new studies underway. - This milestone represents a significant advancement in gene and cell therapy capabilities in the Middle East region. - The achievement aligns with Saudi Vision 2030 objectives and reinforces KFSHRC's position as a leader in pioneering healthcare research.
- King Faisal Specialist Hospital & Research Centre successfully treated eight hemophilia A patients with one-time gene therapy, eliminating the need for preventive treatment and significantly improving quality of life. - The hospital became the first in Saudi Arabia to locally produce CAR-T cells in 2024, marking a major step toward national self-sufficiency in advanced cancer therapies. - KFSHRC now conducts 52.4% of all active clinical trials nationwide and recorded 701 active research proposals by the end of 2024, representing an 8% increase over the previous year.
- Dr. Simrit Parmar at Texas A&M University has developed an innovative umbilical cord blood-derived T regulatory cell therapy that has demonstrated safety and efficacy in treating over 80 patients with ALS and other inflammatory diseases. - The therapy addresses inflammation using Treg cells that do not require donor-recipient matching and can be manufactured at scale from a single cord blood unit, with products remaining viable for up to three years when frozen. - Recent studies published in NEJM Evidence showed functional improvement in ALS patients following multiple infusions, while a historic partnership with Saudi Arabia's King Faisal Specialist Hospital will launch new clinical trials. - Dr. Parmar aims to secure FDA regulatory approval within two years for aplastic anemia treatment while seeking expanded funding for larger ALS patient studies in the United States.
- King Faisal Specialist Hospital & Research Centre and Cellenkos Inc. have signed a strategic MOU to develop T regulatory cell therapies for rare diseases with unmet medical needs, marking the first clinical trial alliance between Saudi Arabia and the US. - The partnership will initially focus on clinical trials for Graft vs. Host Disease and Aplastic Anemia, with plans to expand into neurodegenerative diseases like ALS and cardiovascular disorders. - Cellenkos will support KFSHRC in building local infrastructure for cell and gene therapy manufacturing, leveraging the hospital's cord blood bank to optimize scalability and improve patient access.
- King Faisal Specialist Hospital & Research Centre (KFSHRC) strengthens its clinical research leadership through its Clinical Trials Transformation Initiative, launched in 2021. - In 2023, KFSHRC initiated 140 new clinical trials, providing over 1,200 patients access to innovative therapies and significantly improving patient outcomes. - Partnerships with SNIH and SFDA expedite clinical trial approvals, ensuring treatments reach patients swiftly while adhering to stringent safety and efficacy standards. - KFSHRC's efforts include community engagement, such as the Clinical Trials Awareness Campaign, to promote public understanding and encourage volunteer participation in clinical research.
